Last reviewed · How we verify
Omega-3 fish oil lipid emulsion
Omega-3 fish oil lipid emulsion provides essential polyunsaturated fatty acids (EPA and DHA) that reduce inflammation and support cellular function.
Omega-3 fish oil lipid emulsion provides essential polyunsaturated fatty acids (EPA and DHA) that reduce inflammation and support cellular function. Used for Parenteral nutrition supplementation in critically ill or post-operative patients, Prevention of essential fatty acid deficiency in patients unable to tolerate enteral feeding.
At a glance
| Generic name | Omega-3 fish oil lipid emulsion |
|---|---|
| Also known as | Omegaven |
| Sponsor | Kapiolani Medical Center For Women & Children |
| Drug class | Lipid emulsion / Nutritional supplement |
| Modality | Small molecule |
| Therapeutic area | Nutrition / Cardiovascular / Critical Care |
| Phase | Phase 3 |
Mechanism of action
Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are incorporated into cell membranes and act as precursors for anti-inflammatory mediators. They modulate inflammatory pathways, reduce triglycerides, and support cardiovascular and neurological health. The lipid emulsion formulation enables intravenous delivery for patients unable to receive oral supplementation.
Approved indications
- Parenteral nutrition supplementation in critically ill or post-operative patients
- Prevention of essential fatty acid deficiency in patients unable to tolerate enteral feeding
Common side effects
- Hypertriglyceridemia
- Infusion site reactions
- Gastrointestinal upset (if oral formulation)
- Bleeding tendency (at high doses)
Key clinical trials
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
- Preoperative Fish Oil PN and Prognosis After Constipation Surgery
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
- Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients (PHASE4)
- Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation. (PHASE1, PHASE2)
- Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
- Effect of Parenteral Nutrition With n-3 PUFAs on Patients With Intestinal Failure (NA)
- Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: